| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -229,709 | -115,519 |
| Stock-based compensation expense | 72,342 | 46,090 |
| Depreciation and amortization expense | 1,114 | 756 |
| Amortization of debt issuance costs and discount | 1,136 | 807 |
| Amortization and interest accretion related to operating leases | 1,662 | 111 |
| Loss on extinguishment of debt | -2,779 | - |
| Other non-cash items | -612 | -942 |
| Trade receivables, net | 59,463 | 25,409 |
| Prepaid expenses and other current assets | 35,543 | 44,818 |
| Inventory | 35,249 | 29,429 |
| Accounts payable | 337 | -5,624 |
| Accrued liabilities | 220,321 | 32,784 |
| Accrued interest, net of interest received on maturity of investments | 3,568 | 3,366 |
| Net cash used in operating activities | -56,093 | -135,943 |
| Purchases of marketable securities | 834,554 | 356,346 |
| Sales and maturities of marketable securities | 843,151 | 568,082 |
| Acquisition of intangible asset | 3,000 | 0 |
| Purchases of property and equipment, net of disposals | 857 | 0 |
| Net cash provided by (used in) investing activities | 4,740 | 211,736 |
| Proceeds from issuance of debt | 350,000 | - |
| Payment of debt issuance costs | 9,424 | - |
| Repayment of debt | 121,664 | - |
| Proceeds from issuance or sale of equity-Nonrelated Party | 0 | 0 |
| Proceeds from issuance or sale of equity-Related Party | 28,116 | 10,381 |
| Net cash provided by financing activities | 247,028 | 10,381 |
| Net increase in cash, cash equivalents, and restricted cash | 195,675 | 86,174 |
| Cash and cash equivalents at beginning of period | 105,019 | - |
| Cash and cash equivalents at end of period | 300,694 | - |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)